Elite in Hemolytic Anemia

Dr. Sophie M. Lanzkron

Hematology
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
Accepting New Patients
Elite in Hemolytic Anemia
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sophie Lanzkron is a Hematologist in Philadelphia, Pennsylvania. Dr. Lanzkron is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Lanzkron is currently accepting new patients.

Her clinical research consists of co-authoring 165 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 156 articles and participated in 5 clinical trials in the study of Hemolytic Anemia.

Specialties
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Biological, Other
Study Drug: Red Blood Cell
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizuamb
Study Phase: Phase 2
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Other, Drug
Study Drug: SHP655
Study Phase: Phase 1
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: Riociguat
Study Phase: Phase 2
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: May 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

165 Total Publications

Impact of disease- and race-based discrimination in healthcare on pain outcomes among adults living with sickle cell disease in the United States: The mediating roles of internalized stigma and depressive symptoms.
Impact of disease- and race-based discrimination in healthcare on pain outcomes among adults living with sickle cell disease in the United States: The mediating roles of internalized stigma and depressive symptoms.
Journal: Stigma and health
Published: August 26, 2025
Similar Doctors
Advanced in Hemolytic Anemia
Dr. Farzana A. Sayani
Hematology | Hematology Oncology | Oncology
Advanced in Hemolytic Anemia
Dr. Farzana A. Sayani
Hematology | Hematology Oncology | Oncology
3400 Spruce St, 3 Dulles, 
Philadelphia, PA 
 (1.8 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances

Farzana Sayani is a Hematologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Sayani is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Sickle Cell Disease, Thalassemia, Beta Thalassemia, and Hemoglobin SC Disease.

Advanced in Hemolytic Anemia
Dr. Kandace L. Gollomp
Pediatrics | Hematology | Oncology
Advanced in Hemolytic Anemia
Dr. Kandace L. Gollomp
Pediatrics | Hematology | Oncology
34th St. & Civic Center Blvd, The Children's Hospital Of Philadelphia, Room 9nw55, 
Philadelphia, PA 
 (1.9 miles away)
215-590-2437
Languages Spoken:
English
See accepted insurances

Kandace Gollomp is a Pediatrics specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Gollomp is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Alpha Thalassemia, Fetal Edema, Hydrops Fetalis, Vitrectomy, and Bone Marrow Transplant.

Advanced in Hemolytic Anemia
Dr. Joseph N. Tropea
Hematology Oncology | Oncology | Hematology
Advanced in Hemolytic Anemia
Dr. Joseph N. Tropea
Hematology Oncology | Oncology | Hematology

Inspira Health Network Medical Group PC

798 Centerton Rd, 
Pittsgrove, NJ 
 (28.7 miles away)
856-358-6161
Languages Spoken:
English
See accepted insurances

Joseph Tropea is a Hematologist Oncology specialist and an Oncologist in Pittsgrove, New Jersey. Dr. Tropea is rated as an Advanced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, and Congenital Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lanzkron's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile